| NCT04973618 | Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML | WITHDRAWN | PHASE1 | 2025-01 | 2027-01 | 2026-01 |
| NCT06634394 | APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML | RECRUITING | PHASE1 | 2024-10-01 | 2028-03 | 2027-10 |
| NCT05934539 | ALG.APV-527 First-in-human Study | RECRUITING | PHASE1, PHASE2 | 2022-12-23 | 2025-12-01 | 2024-01-01 |
| NCT03768219 | Study to Evaluate APVO210 in Healthy Subjects, Patients With Psoriasis, and Patients With Ulcerative Colitis | TERMINATED | PHASE1 | 2019-03-18 | 2020-06-30 | 2020-06-30 |
| NCT03647800 | Study of APVO436 in Patients With AML or MDS | UNKNOWN | PHASE1 | 2018-12-13 | 2023-06-15 | 2022-12-15 |
| NCT02262910 | Study of ES414 in Metastatic Castration-Resistant Prostate Cancer | COMPLETED | PHASE1 | 2015-01 | 2019-02-18 | 2018-12 |
| NCT01644253 | Phase 1b Safety and Efficacy Study of TRU-016 | TERMINATED | PHASE1 | 2012-09 | 2021-04-21 | 2020-02-24 |
| NCT01317901 | A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma | COMPLETED | PHASE1 | 2011-05 | 2013-06 | 2013-04 |
| NCT01188681 | Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia | COMPLETED | PHASE1, PHASE2 | 2010-09 | 2014-12 | 2014-12 |
| NCT00614042 | Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma | COMPLETED | PHASE1 | 2008-01 | 2012-03 | 2011-12 |